OBJECTIVE: To investigate the application and its trend of oral lipid-regulating drugs in China PLA General Hospital（ hereinafter referred to as"our hospital"） during 2016-2018

so as to provide references for clinical rational drug application and management. METHODS: Through Hospital Information System

data related to oral lipidregulating drugs in our hospital during 2016-2018 were extracted and retrospectively analyzed in terms of consumption sum

defined daily dose system（ DDDs）

defined daily cost（ DDC） and ratio of sequence of consumption sum（ B）/sequence of DDDs（ A）. RESULTS: Among the oral lipid-regulating drugs in our hospital during 2016-2018

the consumption sum of statins had always ranked the first

the top 3 drugs ranked by consumption sum and DDDs in the continuous 3 years were respectively atorvastatin

rosuvastatin and pivastatin; the consumption sum and DDDs of probucol and simvastatin decreased year by year; the consumption sum and DDDs of pravastatin and acipimox were relatively stable; the consumption sum and DDDs of ezetimibe showed significantly increasing trend in 2018

and its ranking rose from 8 th to 4 th; the consumption sum and DDDs of fenofibrate

fluvastatin and policosanol had always been the bottom 3. In the past three years

the DDC of oral lipid-regulating drugs in our hospital decreased year by year; the DDC of policosanol ranks first. The B/A of Probucol was < 1

acipimox was > 1

and the B/A of other lipid-regulating drugs were 1. CONCLUSIONS: The application of oral lipid-regulating drugs in our hospital is basically rational

which meets the medication principle of current guideline recommendation.